We use cookies for a better user experience. Read our Privacy Policy

I Agree

Kinase Inhibitors Market

Kinase Inhibitors Market (Type: Non-receptor Tyrosine Kinase Inhibitors, Receptor Tyrosine Kinase Inhibitors, Multikinase Inhibitors, Serine/Threonine Kinase Inhibitors, Protein Kinase C Inhibitors, RHO Kinase Inhibitors, and Others; Application: Oncology, Inflammatory Diseases, and Others; and Distribution Channel: Hospital Pharmacies, Independent Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Oral JAK Inhibitors Hold Promising Potential for Treatment of Alopecia Areata

Kinase inhibitors are being highly publicized as a potential treatment for alopecia areata (AA). Janus kinase (JAK) inhibitors are being researched for the pathogenesis of alopecia areata, thus revealing that autoreactive cytotoxic T cells are important in the pathway that involves JAK.

Companies in the kinase inhibitors market are collaborating with researchers to carry out single-arm clinical trials, thus revealing the potential of oral JAK inhibitors as therapeutic agents for AA. Potential outcomes suggest that oral JAK inhibitors are effective and substantially tolerable to cases of moderate to severe AA. Researchers in the kinase inhibitors market are increasing efforts to conduct placebo?controlled clinical trials in order to confirm its efficacy and long-term safety.

Recent advancements are being made in anti-angiogenesis receptor tyrosine kinase inhibitors for the treatment of cancer. Angiogenesis is gaining the attention of healthcare companies to develop therapeutic targets for malignant tumors. Companies are achieving success by targeting angiogenesis in various carcinomas.

kinase inhibitors market infographic

To know the scope of our report Get a Sample on Kinase Inhibitors Market

AI Accelerates Drug Discovery for Fibrosis Treatment through Molecular Modeling

The kinase inhibitors market is expected to expand at a modest CAGR of ~4% during the forecast period. However, innovations such as AI are transforming the market for kinase inhibitors. For instance, the U.S. biotechnology startup Insilico Medicine revealed its deep learning system that is capable of identifying potential treatments for fibrosis with the help of DDR1 (Discoidin Domain Receptor 1) kinase inhibitors. 

AI is entering the kinase inhibitors market. Hence, companies should collaborate with biotechnology startups that are capable of integrating target identification with small molecule discovery through AI. Companies are increasing their efficacy in molecular modeling to accelerate drug discovery for fibrosis and other diseases.

Healthcare companies are capitalizing on generative adversarial networks (GANs) to generate novel molecular structures with specified properties. Likewise, deep learning is enabling companies with rapid identification of potent DDR1 kinase inhibitors. Thus, companies are improving their production capabilities to develop a novel drug pipeline of treatment of fibrosis with the help of AI.

Get a glimpse of the in-depth analysis through our Report Brochure

Biochemistry a Key Focus Point for Development of Novel Kinase Inhibitors

Novel assays and profiling techniques are helping companies to develop improved kinase inhibitors for drug development. Discovery of new kinase inhibitors is anticipated to improve biochemical, cellular, and in vivo assays that could offer new therapeutic targets. This is important since oncology is the focus of healthcare providers in the kinase inhibitors space, and research in this field of study is projected to grow exponentially.

Companies in the kinase inhibitors market are increasing R&D to gain expertise in cell signaling for the development of new drugs. The kinase inhibitors market is continuing to grow since the market is largely consolidated with major players accounting to ~68% of the market share. However, developing novel kinase inhibitors poses as a challenge for manufacturers. Hence, manufacturers are collaborating with researchers to acquire a decision-based understanding of kinase biology, cell signaling, and its outcome in various diseases. They are increasing efforts to gain information on biochemical and biophysical assays to examine the potency and selectivity of kinase inhibitors.

Companies Expand Product Portfolio of Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis

Tyrosine kinase inhibitors are being increasingly used for the treatment of autoimmune and inflammatory skin diseases. This is evident since inflammatory diseases application segment is estimated to account for a significant share of the kinase inhibitors market. The global kinase inhibitors market is estimated to reach a value of ~US$ 64.9 Bn by the end of 2027. Owing to excellent multiple signaling processes and disease pathogenesis of tyrosine kinase inhibitors, companies are tapping into incremental opportunities, since these inhibitors serve as novel therapeutic agents for inflammatory and other diseases.

Small molecule tyrosine kinase inhibitors are capable of acquiring pharmacological control in malignant processes, and autoimmune and immune-mediated diseases. Companies in the kinase inhibitors market are expanding their product portfolio in tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. They are increasing efforts to gain approval from health commissions for JAK inhibitors, owing to their effectiveness in the treatment of rheumatoid arthritis.

kinase inhibitors market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report

Analysts’  Viewpoint

Developers are designing immune-modulatory agents for single and combination therapies for the treatment of inflammatory and central nervous system disorders. Companies in the kinase inhibitors market are developing cell assays, since they are more advantageous than biochemical assays, owing to the former’s representation in physiological situation.

Multikinase inhibitors are projected for aggressive growth in the market. However, the effectiveness of multikinase inhibitors is short-lived in RET fusion-positive non-small cell lung cancer. Hence, companies should increase research to find a combination of therapeutics to prevent resistance of multikinase inhibitors toward RET-driven cancer. Companies should tap into opportunities in North America and Asia Pacific, since the kinase inhibitors market in these regions is projected for aggressive growth during the forecast period.

Kinase Inhibitors Market: Overview

  • Various types of kinase inhibitors available in the market such as non-receptor tyrosine kinase inhibitors, receptor tyrosine kinase inhibitors, multikinase inhibitors, serine/threonine kinase inhibitors, protein kinase C inhibitors, RHO kinase inhibitors, and others
  • In terms of revenue generation, the non-receptor tyrosine kinase inhibitors dominated the market. However, growth of the receptor tyrosine kinase inhibitors segment is anticipated to restrain, owing to patent expiry and introduction of generic drugs.

Kinase Inhibitors Market: Drivers

  • Increase in incidence of cancer patients among population is the major cause of growth of the global kinase inhibitors market. According to the Cancer Research UK data, around 17 million new cases of cancer were reported worldwide in 2018 and around 27.5 million new cases of cancer are likely to be reported worldwide each year by 2040.
  • Expanding indications of existing and pipeline kinase inhibitors also boost the market growth. BCR-ABL TKIs, which were earlier approved for treating CML, are now indicated for treating acute lymphoblastic leukemia (ALL) and gastrointestinal tumors. Similarly, EGFR TKIs are approved for an array of indications such as pancreatic cancer, breast cancer, and non-small cell lung cancer.

Market Segmentation: Kinase Inhibitors Market

  • Based on type, the global kinase inhibitors market has been divided into non-receptor tyrosine kinase inhibitors, receptor tyrosine kinase inhibitors, multikinase inhibitors, serine/threonine kinase inhibitors, protein kinase C Inhibitors, RHO kinase inhibitors, and others. The non-receptor tyrosine kinase inhibitors segment is further sub-segmented into Bruton's tyrosine kinase (BTK) inhibitors, BCR-ABL, Janus kinase (JAK) inhibitor, mesenchymal epithelial transition growth factor (c-MET), spleen tyrosine kinase (SYK) inhibitors, and others. Receptor tyrosine kinase is again divided into VEGFR, PDGFR, EGFR, ALK, HER2, and others.
  • In terms of application, the kinase inhibitors market has been categorized into oncology, inflammatory diseases, and others. Oncology is further divided into lung cancer, renal cell cancer, breast cancer, and others.
  • Based on distribution channel, the global kinase inhibitors market has been segmented into hospital pharmacies, independent pharmacies, and online pharmacies
  • Each of the segments has been analyzed in detail for market trends, recent trends and developments, drivers, restraints, opportunities, and useful insights. The report provides current and future revenue (US$ Mn) for each of these segments for the period from 2017 to 2027, considering 2018 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2019 to 2027 along with market size estimations.

Regional Overview: Kinase Inhibitors Market

  • In terms of region, the global kinase inhibitors market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been further divided into major countries and sub-regions.
  • The current and future market sizes in terms of revenue (US$ Mn) of these regional markets and their major countries have been provided in the report for the period from 2017 to 2027, with their CAGRs for the period from 2019 to 2027
  • The study also offers a list of recommendations, highlights, and useful insights of the market which is likely to help new companies willing to enter the market and existing companies to increase market shares and help in the decision-making process

Major Players

  • The report concludes with the company profiles section that includes key information about the major players in the market
  • Leading players analyzed in the report are
    • Novartis AG,
    • Pfizer,
    • Johnson & Johnson,
    • AstraZeneca,
    • Bristol-Myers Squibb,
    • Boehringer Ingelheim International GmbH,
    • Bayer AG, F.
    • Hoffmann-La Roche Ltd, 
    • Eisai Co., Ltd
  • Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Kinase Inhibitors Market – Segmentation

TMR’s study on the global kinase inhibitors market includes information divided into: type, application, distribution channel, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global kinase inhibitors market have been discussed in detail.

Type

 

  • Non-receptor Tyrosine Kinase Inhibitors
    • Bruton’s Tyrosine Kinase (BTK) Inhibitors
    • BCR-ABL
    • Janus Kinase (JAK) Inhibitor
    • Mesenchymal Epithelial Transition Growth Factor (c-MET)
    • Spleen Tyrosine Kinase (SYK) Inhibitors
    • Others
  • Receptor Tyrosine Kinase Inhibitors
    • VEGFR
    • PDGFR
    • EGFR
    • ALK
    • HER2
    • Others
  • Multikinase inhibitors
  • Serine/Threonine Kinase Inhibitors
  • Protein Kinase C Inhibitors
  • RHO Kinase Inhibitors
  • Others


Application

 

  • Oncology
    • Lung Cancer
    • Renal Cell Cancer
    • Breast Cancer
    • Others
  • Inflammatory Diseases
  • Others


Distribution Channel

 

  • Hospital Pharmacies
  • Independent Pharmacies
  • Online Pharmacies


Region

 

  • North America
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Kinase Inhibitors Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of kinase inhibitors market?

Kinase inhibitors market is estimated to reach a value of ~US$ 64.9 Bn by the end of 2027

What is the anticipated CAGR of the kinase inhibitors market in the forecast period?

Kinase inhibitors market is projected to expand at a CAGR of ~4% from 2019 to 2027

What are the key driving factors for the growth of the kinase inhibitors market?

Kinase inhibitors market is driven by increase in incidence of cancer patients among population

Which region is expected to project the highest market share in the global kinase inhibitors market?

North America accounted for major share of the global kinase inhibitors market, owing to introduction of new drugs

Who are the key players in the global kinase inhibitors market?

Key players in the global kinase inhibitors market include Novartis AG, Pfizer, Johnson & Johnson, AstraZeneca, Bristol-Myers Squibb

1.  Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Kinase Inhibitors Market

4. Market Overview

    4.1.  Introduction & Overview

    4.2. Market Dynamics

        4.2.1. Drivers

        4.2.2. Restraints

        4.2.3. Opportunities 

    4.3. Porter’s Five Forces Analysis

    4.4. Global Kinase Inhibitors Market Analysis and Forecast, 2017–2027

5. Market Outlook 

    5.1. Pipeline Analysis

    5.2. Brand Analysis

    5.3. Recent Developments In Kinase Inhibitors Research 

6. Global Kinase Inhibitors Market Analysis and Forecasts, by Type

    6.1. Introduction & Definition

    6.2. Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

        6.2.1. Non-receptor Tyrosine Kinase Inhibitors

            6.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors

            6.2.1.2. BCR-ABL

            6.2.1.3. Janus Kinase (JAK) Inhibitor

            6.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)

            6.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors

            6.2.1.6. Others

        6.2.2. Receptor Tyrosine Kinase Inhibitors

            6.2.2.1. VEGFR

            6.2.2.2. PDGFR

            6.2.2.3. EGFR

            6.2.2.4. ALK

            6.2.2.5. HER2

            6.2.2.6. Others

        6.2.3. Multikinase inhibitors

        6.2.4. Serine/Threonine Kinase Inhibitors

        6.2.5. Protein Kinase C Inhibitors

        6.2.6. RHO Kinase Inhibitors

        6.2.7. Others 

    6.3. Global Kinase Inhibitors Market Attractiveness, by Type

7. Global Kinase Inhibitors Market Analysis and Forecasts, by Application

    7.1. Introduction & Definition

    7.2. Global Kinase Inhibitors Market Value (US$) Forecast, by Application, 2017–2027

        7.2.1. Oncology

            7.2.1.1. Lung Cancer

            7.2.1.2. Renal cell cancer

            7.2.1.3. Breast Cancer

            7.2.1.4. Others

        7.2.2. Inflammatory Diseases

        7.2.3. Others 

    7.3. Global Kinase Inhibitors Market Attractiveness, by Application

8. Global Kinase Inhibitors Market Analysis and Forecasts, by Distribution Channel

    8.1. Introduction & Definition

    8.2. Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        8.2.1. Hospital Pharmacies

        8.2.2. Independent Pharmacies

        8.2.3. Online Pharmacies

    8.3. Global Kinase Inhibitors Market Attractiveness, by Distribution Channel

9. Global Kinase Inhibitors Market Analysis and Forecasts, by Region

    9.1. Key Findings

    9.2. Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Global Kinase Inhibitors Market Attractiveness, by Region

10. North America Kinase Inhibitors Market Analysis and Forecast

    10.1. Introduction

    10.2. North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

        10.2.1. Non-receptor Tyrosine Kinase Inhibitors

            10.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors

            10.2.1.2. BCR-ABL

            10.2.1.3. Janus Kinase (JAK) Inhibitor

            10.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)

            10.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors

            10.2.1.6. Others

        10.2.2. Receptor Tyrosine Kinase Inhibitors

            10.2.2.1. VEGFR

            10.2.2.2. PDGFR

            10.2.2.3. EGFR

            10.2.2.4. ALK

            10.2.2.5. HER2

            10.2.2.6. Others

        10.2.3. Multikinase inhibitors

        10.2.4. Serine/Threonine Kinase Inhibitors

        10.2.5. Protein Kinase C Inhibitors

        10.2.6. RHO Kinase Inhibitors

        10.2.7. Others 

    10.3. North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027

        10.3.1. Oncology

            10.3.1.1. Lung Cancer

            10.3.1.2. Renal cell cancer

            10.3.1.3. Breast Cancer

            10.3.1.4. Others

        10.3.2. Inflammatory Diseases

        10.3.3. Others

    10.4. North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        10.4.1. Hospital Pharmacies

        10.4.2. Independent Pharmacies

        10.4.3. Online Pharmacies

    10.5. North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country, 2017–2027

        10.5.1. U.S.

        10.5.2. Canada

    10.6. North America Kinase Inhibitors Market Attractiveness Analysis

        10.6.1. By Type

        10.6.2. By Application

        10.6.3. By Distribution Channel

        10.6.4. By Country 

11. Europe Kinase Inhibitors Market Analysis and Forecast

    11.1. Introduction

    11.2. Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

        11.2.1. Non-receptor Tyrosine Kinase Inhibitors

            11.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors

            11.2.1.2. BCR-ABL

            11.2.1.3. Janus Kinase (JAK) Inhibitor

            11.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)

            11.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors

            11.2.1.6. Others

        11.2.2. Receptor Tyrosine Kinase Inhibitors

            11.2.2.1. VEGFR

            11.2.2.2. PDGFR

            11.2.2.3. EGFR

            11.2.2.4. ALK

            11.2.2.5. HER2

            11.2.2.6. Others

        11.2.3. Multikinase inhibitors

        11.2.4. Serine/Threonine Kinase Inhibitors

        11.2.5. Protein Kinase C Inhibitors

        11.2.6. RHO Kinase Inhibitors

        11.2.7. Others 

    11.3. Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027

        11.3.1. Oncology

            11.3.1.1. Lung Cancer

            11.3.1.2. Renal cell cancer

            11.3.1.3. Breast Cancer

            11.3.1.4. Others

        11.3.2. Inflammatory Diseases

        11.3.3. Others

    11.4. Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        11.4.1. Hospital Pharmacies

        11.4.2. Independent Pharmacies

        11.4.3. Online Pharmacies

    11.5. Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Europe Kinase Inhibitors Market Attractiveness Analysis

        11.6.1. By Type

        11.6.2. By Application

        11.6.3. By Distribution Channel

        11.6.4. By Country/Sub-region

12. Asia Pacific Kinase Inhibitors Market Analysis and Forecast

    12.1. Introduction

    12.2. Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

        12.2.1. Non-receptor Tyrosine Kinase Inhibitors

            12.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors

            12.2.1.2. BCR-ABL

            12.2.1.3. Janus Kinase (JAK) Inhibitor

            12.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)

            12.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors

            12.2.1.6. Others

        12.2.2. Receptor Tyrosine Kinase Inhibitors

            12.2.2.1. VEGFR

            12.2.2.2. PDGFR

            12.2.2.3. EGFR

            12.2.2.4. ALK

            12.2.2.5. HER2

            12.2.2.6. Others

        12.2.3. Multikinase inhibitors

        12.2.4. Serine/Threonine Kinase Inhibitors

        12.2.5. Protein Kinase C Inhibitors

        12.2.6. RHO Kinase Inhibitors

        12.2.7. Others 

    12.3. Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027

        12.3.1. Oncology

            12.3.1.1. Lung Cancer

            12.3.1.2. Renal cell cancer

            12.3.1.3. Breast Cancer

            12.3.1.4. Others

        12.3.2. Inflammatory Diseases

        12.3.3. Others

    12.4. Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        12.4.1. Hospital Pharmacies

        12.4.2. Independent Pharmacies

        12.4.3. Online Pharmacies

    12.5. Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Asia Pacific Kinase Inhibitors Market Attractiveness Analysis

        12.6.1. By Type

        12.6.2. By Application

        12.6.3. By Distribution Channel

        12.6.4. By Country/Sub-region

13. Latin America Kinase Inhibitors Market Analysis and Forecast

    13.1. Introduction

    13.2. Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

        13.2.1. Non-receptor Tyrosine Kinase Inhibitors

            13.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors

            13.2.1.2. BCR-ABL

            13.2.1.3. Janus Kinase (JAK) Inhibitor

            13.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)

            13.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors

            13.2.1.6. Others

        13.2.2. Receptor Tyrosine Kinase Inhibitors

            13.2.2.1. VEGFR

            13.2.2.2. PDGFR

            13.2.2.3. EGFR

            13.2.2.4. ALK

            13.2.2.5. HER2

            13.2.2.6. Others

        13.2.3. Multikinase inhibitors

        13.2.4. Serine/Threonine Kinase Inhibitors

        13.2.5. Protein Kinase C Inhibitors

        13.2.6. RHO Kinase Inhibitors

        13.2.7. Others 

    13.3. Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027

        13.3.1. Oncology

            13.3.1.1. Lung Cancer

            13.3.1.2. Renal cell cancer

            13.3.1.3. Breast Cancer

            13.3.1.4. Others

        13.3.2. Inflammatory Diseases

        13.3.3. Others

    13.4. Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        13.4.1. Hospital Pharmacies

        13.4.2. Independent Pharmacies

        13.4.3. Online Pharmacies

    13.5. Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Latin America Kinase Inhibitors Market Attractiveness Analysis

        13.6.1. By Type

        13.6.2. By Application

        13.6.3. By Distribution Channel

        13.6.4. By Country/Sub-region

14. Middle East & Africa Kinase Inhibitors Market Analysis and Forecast

    14.1. Introduction

    14.2. Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

        14.2.1. Non-receptor Tyrosine Kinase Inhibitors

            14.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors

            14.2.1.2. BCR-ABL

            14.2.1.3. Janus Kinase (JAK) Inhibitor

            14.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)

            14.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors

            14.2.1.6. Others

        14.2.2. Receptor Tyrosine Kinase Inhibitors

            14.2.2.1. VEGFR

            14.2.2.2. PDGFR

            14.2.2.3. EGFR

            14.2.2.4. ALK

            14.2.2.5. HER2

            14.2.2.6. Others

        14.2.3. Multikinase inhibitors

        14.2.4. Serine/Threonine Kinase Inhibitors

        14.2.5. Protein Kinase C Inhibitors

        14.2.6. RHO Kinase Inhibitors

        14.2.7. Others 

    14.3. Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027

        14.3.1. Oncology

            14.3.1.1. Lung Cancer

            14.3.1.2. Renal cell cancer

            14.3.1.3. Breast Cancer

            14.3.1.4. Others

        14.3.2. Inflammatory Diseases

        14.3.3. Others

    14.4. Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        14.4.1. Hospital Pharmacies

        14.4.2. Independent Pharmacies

        14.4.3. Online Pharmacies

    14.5. Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Israel

        14.5.4. Rest of Middle East & Africa

    14.6. Middle East & Africa Kinase Inhibitors Market Attractiveness Analysis

        14.6.1. By Type

        14.6.2. By Application

        14.6.3. By Distribution Channel

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Competition Matrix

    15.2. Market Share Analysis, by Company (2018)

    15.3. Company Profiles

        15.3.1. Boehringer Ingelheim International GmbH

            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.1.2. Company Financials

            15.3.1.3. Growth Strategies

            15.3.1.4. SWOT Analysis

        15.3.2. Novartis AG 

            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.2.2. Company Financials

            15.3.2.3. Growth Strategies

            15.3.2.4. SWOT Analysis

        15.3.3. AstraZeneca plc 

            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.3.2. Company Financials

            15.3.3.3. Growth Strategies

            15.3.3.4. SWOT Analysis

        15.3.4. Pfizer, Inc. 

            15.3.4.1. Company Overview (HQ, Business Segments)

            15.3.4.2. Company Financials

            15.3.4.3. Growth Strategies

            15.3.4.4. SWOT Analysis

        15.3.5. F. Hoffmann-La Roche Ltd

            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.5.2. Company Financials

            15.3.5.3. Growth Strategies

            15.3.5.4. SWOT Analysis

        15.3.6. Bristol-Myers Squibb Company

            15.3.6.1. Company Overview (HQ, Business Segments)

            15.3.6.2. Company Financials

            15.3.6.3. Growth Strategies

            15.3.6.4. SWOT Analysis

        15.3.7. Johnson & Johnson 

            15.3.7.1. Company Overview (HQ, Business Segments)

            15.3.7.2. Company Financials

            15.3.7.3. Growth Strategies

            15.3.7.4. SWOT Analysis

        15.3.8. Bayer AG

            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.8.2. Company Financials

            15.3.8.3. Growth Strategies

            15.3.8.4. SWOT Analysis

        15.3.9. Eisai Co., Ltd. 

            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.9.2. Company Financials

            15.3.9.3. Growth Strategies

            15.3.9.4. SWOT Analysis

List of Tables

Table 01: Global BCR-ABL Tyrosine Kinase Inhibitors Market Revenue (US$ Mn) Forecast, by Key Brands, 2016-2026

Table 02: Global EGFR Tyrosine Kinase Inhibitors Market Revenue (US$ Mn) Forecast, by Key Brands, 2016-2026

Table 03: Global VEGFR Tyrosine Kinase Inhibitors Market Revenue (US$ Mn) Forecast, by Key Brands, 2016-2026

Table 04: Global Other Tyrosine Kinase Inhibitors Market Revenue (US$ Mn) Forecast, by Key Brands, 2016-2026

Table 05: Patent & Market Exclusivity Overview, by Molecule (1/4)

Table 06: Patent & Market Exclusivity Overview, by Molecule (2/4)

Table 07: Patent & Market Exclusivity Overview, by Molecule (3/4)

Table 08: Patent & Market Exclusivity Overview, by Molecule (4/4)

Table 09: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

Table 10: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Non-receptor Tyrosine Kinase Inhibitors, 2017–2027

Table 11: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Receptor Tyrosine Kinase Inhibitors, 2017–2027

Table 12: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027

Table 13: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Oncology, 2017–2027

Table 14: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 15: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 16: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

Table 17: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Non-receptor Tyrosine Kinase Inhibitors, 2017–2027

Table 18: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Receptor Tyrosine Kinase Inhibitors, 2017–2027

Table 19: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027

Table 20: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Oncology, 2017–2027

Table 21: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 22: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 23: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

Table 24: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Non-receptor Tyrosine Kinase Inhibitors, 2017–2027

Table 25: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Receptor Tyrosine Kinase Inhibitors, 2017–2027

Table 26: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027

Table 27: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Oncology, 2017–2027

Table 28: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 29: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 30: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

Table 31: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Non-receptor Tyrosine Kinase Inhibitors, 2017–2027

Table 32: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Receptor Tyrosine Kinase Inhibitors, 2017–2027

Table 33: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027

Table 34: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Oncology, 2017–2027

Table 35: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 36: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 37: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

Table 38: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Non-receptor Tyrosine Kinase Inhibitors, 2017–2027

Table 39: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Receptor Tyrosine Kinase Inhibitors, 2017–2027

Table 40: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027

Table 41: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Oncology, 2017–2027

Table 42: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 43: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 44: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

Table 45: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Non-receptor Tyrosine Kinase Inhibitors, 2017–2027

Table 46: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Receptor Tyrosine Kinase Inhibitors, 2017–2027

Table 47: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027

Table 48: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Oncology, 2017–2027

Table 49: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 50: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

List of Figures

Figure 01: Global Kinase Inhibitors Market Value (US$ Mn) and Distribution (%), by Region, 2018 and 2027

Figure 02: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, 2017–2027

Figure 03: Clinical Trial Analysis, by Phase

Figure 04: Clinical Trial Analysis, by Status

Figure 05: Global Kinase Inhibitors Market Value Share Analysis, by Type, 2018 and 2027

Figure 06: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Non-receptor Tyrosine Kinase Inhibitors, 2017–2027

Figure 07: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Receptor Tyrosine Kinase Inhibitors, 2017–2027

Figure 08: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Multikinase inhibitors, 2017–2027

Figure 09: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Serine/Threonine Kinase Inhibitors, 2017–2027

Figure 10: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Protein Kinase C Inhibitors, 2017–2027

Figure 11: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by RHO Kinase Inhibitors, 2017–2027

Figure 12: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2017–2027

Figure 13: Global Kinase Inhibitors Market Attractiveness Analysis, by Type, 2019–2027

Figure 14: Global Kinase Inhibitors Market Value Share Analysis, by Application, 2018 and 2027

Figure 15: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Oncology, 2017–2027

Figure 16: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Inflammatory Diseases, 2017–2027

Figure 17: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2017–2027

Figure 18: Global Kinase Inhibitors Market Attractiveness Analysis, by Application, 2019–2027

Figure 19: Global Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 20: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Independent Pharmacies, 2017–2027

Figure 21: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hospital Pharmacies, 2017–2027

Figure 22: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Online Pharmacies, 2017–2027

Figure 23: Global Kinase Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 24: Global Kinase Inhibitors Market Value Share Analysis, by Region, 2018 and 2027

Figure 25: Global Kinase Inhibitors Market Attractiveness Analysis, by Region, 2019–2027

Figure 26: North America Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 27: North America Kinase Inhibitors Market Value Share Analysis, by Type, 2018 and 2027

Figure 28: North America Kinase Inhibitors Market Attractiveness Analysis, by Type, 2019–2027

Figure 29: North America Kinase Inhibitors Market Value Share Analysis, by Application, 2018 and 2027

Figure 30: North America Kinase Inhibitors Market Attractiveness Analysis, by Application, 2019–2027

Figure 31: North America Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 32: North America Kinase Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 33: North America Kinase Inhibitors Market Value Share Analysis, by Country, 2018 and 2027

Figure 34: North America Kinase Inhibitors Market Attractiveness Analysis, by Country, 2019–2027

Figure 35: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 36: Europe Kinase Inhibitors Market Value Share Analysis, by Type, 2018 and 2027

Figure 37: Europe Kinase Inhibitors Market Attractiveness Analysis, by Type, 2019–2027

Figure 38: Europe Kinase Inhibitors Market Value Share Analysis, by Application, 2018 and 2027

Figure 39: Europe Kinase Inhibitors Market Attractiveness Analysis, by Application, 2019–2027

Figure 40: Europe Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 41: Europe Kinase Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 42: Europe Kinase Inhibitors Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 43: Europe Kinase Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 44: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 45: Asia Pacific Kinase Inhibitors Market Value Share Analysis, by Type, 2018 and 2027

Figure 46: Asia Pacific Kinase Inhibitors Market Attractiveness Analysis, by Type, 2019–2027

Figure 47: Asia Pacific Kinase Inhibitors Market Value Share Analysis, by Application, 2018 and 2027

Figure 48: Asia Pacific Kinase Inhibitors Market Attractiveness Analysis, by Application, 2019–2027

Figure 49: Asia Pacific Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 50: Asia Pacific Kinase Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 51: Asia Pacific Kinase Inhibitors Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 52: Asia Pacific Kinase Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 53: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 54: Latin America Kinase Inhibitors Market Value Share Analysis, by Type, 2018 and 2027

Figure 55: Latin America Kinase Inhibitors Market Attractiveness Analysis, by Type, 2019–2027

Figure 56: Latin America Kinase Inhibitors Market Value Share Analysis, by Application, 2018 and 2027

Figure 57: Latin America Kinase Inhibitors Market Attractiveness Analysis, by Application, 2019–2027

Figure 58: Latin America Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 59: Latin America Kinase Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 60: Latin America Kinase Inhibitors Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 61: Latin America Kinase Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 62: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 63: Middle East & Africa Kinase Inhibitors Market Value Share Analysis, by Type, 2018 and 2027

Figure 64: Middle East & Africa Kinase Inhibitors Market Attractiveness Analysis, by Type, 2019–2027

Figure 65: Middle East & Africa Kinase Inhibitors Market Value Share Analysis, by Application, 2018 and 2027

Figure 66: Middle East & Africa Kinase Inhibitors Market Attractiveness Analysis, by Application, 2019–2027

Figure 67: Middle East & Africa Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 68: Middle East & Africa Kinase Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 69: Middle East & Africa Kinase Inhibitors Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 70: Middle East & Africa Kinase Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 71: Global Kinase Inhibitors Market Share, by Company, 2018

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

253

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved